Fig. 1.
Fig. 1. Expression of α4-integrin and VCAM-1 in 5TGM1 myeloma cells and in stromal cells. / (Ai) Expression of α4-integrin determined by RT-PCR. Lane 1, 5TGM1 myeloma cells; lane 2, ST2 stromal cells. (Aii), GAPDH as control. (Aiii) Expression of VCAM-1 mRNA determined by RT-PCR. Lane 1, ST2 mouse bone marrow stromal cells; lane 2, primary mouse bone marrow stromal cells; lane 3, 5TGM1 myeloma cells. (Aiv), GAPDH as control. (B) Flow cytometric analysis of VCAM-1 (Bi,Biii) and α4-integrin (Bii,Biv) expression on the cell surface of ST2 bone marrow cells (Bi,Bii) and 5TGM1 myeloma cells (Biii,Biv). Solid line indicates anti–VCAM-1 antibody (Bi,Biii), anti-α4-integrin antibody (Bii,Biv); dotted line, no primary antibody. Analysis was conducted as described in text.

Expression of α4-integrin and VCAM-1 in 5TGM1 myeloma cells and in stromal cells.

(Ai) Expression of α4-integrin determined by RT-PCR. Lane 1, 5TGM1 myeloma cells; lane 2, ST2 stromal cells. (Aii), GAPDH as control. (Aiii) Expression of VCAM-1 mRNA determined by RT-PCR. Lane 1, ST2 mouse bone marrow stromal cells; lane 2, primary mouse bone marrow stromal cells; lane 3, 5TGM1 myeloma cells. (Aiv), GAPDH as control. (B) Flow cytometric analysis of VCAM-1 (Bi,Biii) and α4-integrin (Bii,Biv) expression on the cell surface of ST2 bone marrow cells (Bi,Bii) and 5TGM1 myeloma cells (Biii,Biv). Solid line indicates anti–VCAM-1 antibody (Bi,Biii), anti-α4-integrin antibody (Bii,Biv); dotted line, no primary antibody. Analysis was conducted as described in text.

Close Modal

or Create an Account

Close Modal
Close Modal